Abcuro, Inc. announced initiation of a Phase I/II dose escalation trial to evaluate the safety, tolerability, and proof-of-concept of ABC008 in patients with T cell large granular lymphocytic leukemia who suffer from anemia and/or neutropenia.
[Abcuro, Inc.]
